Journal of Medical Economics
Volume 24, 2021 - Issue 1
Haematology
Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment
Ali McBridea The University of Arizona Cancer Center, Tucson, AZ, USA;b Department of Pharmacy Practice and Science, The University of Arizona College of Pharmacy, Tucson, AZ, USA;c Banner University Medical Center, Tucson, AZ, USA
https://orcid.org/0000-0002-9430-4675
https://orcid.org/0000-0002-9430-4675, Karen MacDonaldd Matrix45, Tucson, AZ, USAhttps://orcid.org/0000-0002-4568-9783
https://orcid.org/0000-0002-4568-9783, Adolfo Fuentes-Alburoe Viatris Inc, Canonsburg, PA, USAhttps://orcid.org/0000-0003-0564-2507
https://orcid.org/0000-0003-0564-2507 & Ivo Abrahama The University of Arizona Cancer Center, Tucson, AZ, USA;b Department of Pharmacy Practice and Science, The University of Arizona College of Pharmacy, Tucson, AZ, USA;d Matrix45, Tucson, AZ, USA;f Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USACorrespondence[email protected]
https://orcid.org/0000-0003-0490-4421
https://orcid.org/0000-0003-0490-4421